In particular, some of these studies involved incomplete examination of expression of CD155 (n = 2); TCGA studies (n = 5); cancer-specific survival, relapse-free survival, and disease-free survival studies (n = 6); the absence of survival data (n = 3); and animal or cell research (n = 4). The gene discussed is PVR; the disease is cancer.